A low expression of HOXD13 correlated to better survival in IDHmut grade 3 patients, which supported previous data indicating that a hypermethylation of HOXD13 was observed in IDH-mutated GBM-patient long-term survivors, compared to short-term survivors [28]. The gene discussed is HOXD13; the disease is glioblastoma.